Efalizumab, a monoclonal antibody against CD11a which blocks the interaction of LFA-1 and its ligand, ICAM-1, has been shown to ameliorate psoriatic skin lesions, but it was not effective in the treatment of psoriatic arthritis [76]. This evidence concerns the gene ITGAL and psoriatic arthritis.